Understanding a TRMA Diagnosis

At a Glance

TRMA (Rogers syndrome) is a rare inherited disorder caused by an SLC19A2 gene change that disrupts thiamine transport. Lifelong high-dose oral thiamine can improve anemia and help manage diabetes, but usually cannot reverse established hearing loss.

Receiving a diagnosis of Thiamine-Responsive Megaloblastic Anemia (TRMA) often marks the end of a long and exhausting search for answers. This condition—also known as Rogers syndrome—is an ultra-rare genetic disorder that affects how the body uses energy ^[1]^[2]. Because it is so rare, you may find that many doctors have never encountered it before ^[1]^[3].

Understanding the Diagnosis

TRMA is an autosomal recessive condition caused by a change (mutation) in the SLC19A2 gene ^[2]. This gene is responsible for making a protein that acts like a specialized “doorway” or transporter, allowing thiamine (Vitamin B1) to enter your cells ^[4].

In a person with TRMA, these doorways do not work correctly. Even if there is plenty of thiamine in the diet, it cannot get inside the cells where it is needed ^[5]. Thiamine is essential for cells to turn food into energy; without it, certain parts of the body begin to struggle ^[6]. The three areas most commonly affected are:

The Blood: The body cannot make healthy red blood cells, leading to megaloblastic anemia (large, abnormally shaped red blood cells) ^[7].
The Pancreas: Cells that produce insulin cannot function properly, which can lead to diabetes ^[8].
The Ears: The delicate cells in the inner ear are very sensitive to thiamine levels, and a lack of thiamine can lead to hearing loss ^[9].

The Emotional Journey

The path to a TRMA diagnosis is rarely a straight line. Many families experience a “diagnostic odyssey,” spending years visiting different specialists and undergoing numerous tests before the correct cause is found ^[10].

It is completely normal to feel a complex mix of emotions right now:

Relief: Finally having a name for your child’s condition and a clear treatment path can be a profound weight off your shoulders ^[11].
Anxiety: Learning that a condition is “ultra-rare” can feel isolating. You may worry about the future or about whether your local medical team has the specialized knowledge needed to manage it ^[12].
Grief: Processing the reality of a lifelong genetic condition and the challenges your child has already faced can be deeply painful ^[13].

Caregivers of children with rare diseases often carry an enormous load, acting as researchers, advocates, and medical coordinators all at once ^[14]. Acknowledging the physical and emotional strain you are under is a vital part of caring for your child and yourself ^[15].

The Role of Thiamine

The defining feature of TRMA is its response to treatment. While the body cannot transport thiamine through its usual “high-affinity” doorways, it can still absorb thiamine through other lower-affinity pathways if the dose is high enough ^[16].

The standard, established treatment for TRMA is lifelong, high-dose oral thiamine ^[2]. When started early, this treatment is highly effective at helping the body produce healthy blood cells and can often help manage blood sugar levels ^[16]^[17]. While thiamine is very successful at treating the anemia, it usually cannot reverse hearing loss that has already occurred, though it is a critical part of overall health management ^[18]^[2].

Moving Forward

Because TRMA is so rare, you are a vital partner in your child’s care, supported by a named clinical lead and outside experts. Building a care team that values your input and is willing to consult with international specialists is key. While the diagnosis is lifelong, the clarity it provides allows you to focus on the most effective ways to support your child’s growth and health ^[19].

Common questions in this guide

What causes TRMA, also called Rogers syndrome?

TRMA is caused by changes in the SLC19A2 gene and is inherited in a recessive pattern, meaning a child usually receives a changed copy from each parent. The gene normally helps transport thiamine, or vitamin B1, into cells; in TRMA, this transport system does not work properly.

What health problems are part of TRMA?

The classic TRMA pattern affects three areas: blood-cell production, insulin-producing cells in the pancreas, and the inner ear. This can lead to megaloblastic anemia, diabetes, and hearing loss, and the care team monitors all three areas.

How is TRMA treated with thiamine?

The established treatment is lifelong, high-dose oral thiamine, also called vitamin B1. Starting it early can help the body make healthy red blood cells and can often help manage blood sugar, but it usually cannot reverse hearing loss that has already occurred.

Why can high-dose thiamine help if TRMA affects thiamine transport?

TRMA disrupts the body’s usual high-affinity thiamine transport pathway, but cells can still take up thiamine through lower-affinity pathways when the dose is high enough. This is why high-dose treatment can work even though the primary transporter is not functioning normally.

What should families do after a TRMA diagnosis?

Because TRMA is very rare, families often benefit from a coordinated team with a named clinical lead and access to outside or international experts. Keeping communication organized across specialists and seeking emotional and practical support can help with the long-term care plan.

Get notified when new evidence is published on Thiamine-responsive megaloblastic anemia syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References (19)

1
First 2 cases with thiamine-responsive megaloblastic anemia in the Czech Republic, a rare form of monogenic diabetes mellitus: a novel mutation in the thiamine transporter SLC19A2 gene-intron 1 mutation c.204+2T>G.
Pomahačová R, Zamboryová J, Sýkora J, et al.
Pediatric diabetes 2017; (18(8)):844-847 doi:10.1111/pedi.12479.
PMID: 28004468
2
[Thiamine-responsive megaloblastic anemia or Rogers syndrome: A literature review].
Lu H, Lu H, Vaucher J, et al.
La Revue de medecine interne 2019; (40(1)):20-27 doi:10.1016/j.revmed.2018.06.005.
PMID: 30031565
3
Identification of novel compound heterozygous variants in SLC19A2 and the genotype-phenotype associations in thiamine-responsive megaloblastic anemia.
Zhang S, Qiao Y, Wang Z, et al.
Clinica chimica acta; international journal of clinical chemistry 2021; (516()):157-168 doi:10.1016/j.cca.2021.01.025.
PMID: 33571483
4
The Effects of Genetic Mutations and Drugs on the Activity of the Thiamine Transporter, SLC19A2.
Enogieru OJ, Koleske ML, Vora B, et al.
The AAPS journal 2021; (23(2)):35 doi:10.1208/s12248-021-00562-4.
PMID: 33649974
5
Novel nonsense mutation (p.Ile411Metfs*12) in the SLC19A2 gene causing Thiamine Responsive Megaloblastic Anemia in an Indian patient.
Manimaran P, Subramanian VS, Karthi S, et al.
Clinica chimica acta; international journal of clinical chemistry 2016; (452()):44-9.
PMID: 26549656
6
Genetic defects of thiamine transport and metabolism: A review of clinical phenotypes, genetics, and functional studies.
Marcé-Grau A, Martí-Sánchez L, Baide-Mairena H, et al.
Journal of inherited metabolic disease 2019; (42(4)):581-597 doi:10.1002/jimd.12125.
PMID: 31095747
7
Thiamine-Responsive Megaloblastic Anemia Syndrome Mimicking Myelodysplastic Neoplasm.
Klötzer C, Schnabel F, Kubasch AS, et al.
Acta haematologica 2025; (148(4)):380-385 doi:10.1159/000542286.
PMID: 39467528
8
Loss-of-Function Mutation in Thiamine Transporter 1 in a Family With Autosomal Dominant Diabetes.
Jungtrakoon P, Shirakawa J, Buranasupkajorn P, et al.
Diabetes 2019; (68(5)):1084-1093 doi:10.2337/db17-0821.
PMID: 30833467
9
Whole exome sequencing identifies a new mutation in the SLC19A2 gene leading to thiamine-responsive megaloblastic anemia in an Egyptian family.
Amr K, Pawlikowska P, Aoufouchi S, et al.
Molecular genetics & genomic medicine 2019; (7(7)):e00777 doi:10.1002/mgg3.777.
PMID: 31144472
10
Rare diseases in Brazil: a nationwide analysis of the diagnostic odyssey.
de Oliveira BM, Broch MS, de Oliveira CP, et al.
Journal of community genetics 2026; (17(5)).
PMID: 42742802
11
Australian children living with rare diseases: experiences of diagnosis and perceived consequences of diagnostic delays.
Zurynski Y, Deverell M, Dalkeith T, et al.
Orphanet journal of rare diseases 2017; (12(1)):68 doi:10.1186/s13023-017-0622-4.
PMID: 28399928
12
Ultra-rare ultra-care: Assessing the impact of caring for children with ultra rare diseases.
Domaradzki J, Walkowiak D
European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society 2024; (48()):78-84 doi:10.1016/j.ejpn.2023.12.003.
PMID: 38071849
13
Using Interpretative Phenomenological Analysis to Explore the Experiences of Mothers Who Have a Child With the Rare Genetic Disorder, HNRNPU-Related Neurodevelopmental Disorder: "Some Days, I Wear a Cape and I'm Super Mom and Some Days, I Have to Hide Under My Cape and I Can't Get Out for a Few Days".
Overton I, Docherty F, Balasubramanian M
Journal of genetic counseling 2026; (35(5)).
PMID: 42922377
14
"It is like a jungle gym, and everything is under construction": The parent's perspective of caring for a child with a rare disease.
Currie G, Szabo J
Child: care, health and development 2019; (45(1)):96-103 doi:10.1111/cch.12628.
PMID: 30370696
15
Beyond illness severity: transdiagnostic cognitive vulnerabilities as independent predictors of psychological distress in parents of children with rare genetic disorders.
Cuturilo G, Vukosavljevic Gvozden T, Gvozden M, et al.
Frontiers in psychiatry 2026; (17()):1963031 doi:10.3389/fpsyt.2026.1963031.
PMID: 42871252
16
Pharmacogenomics in diabetes: outcomes of thiamine therapy in TRMA syndrome.
Habeb AM, Flanagan SE, Zulali MA, et al.
Diabetologia 2018; (61(5)):1027-1036 doi:10.1007/s00125-018-4554-x.
PMID: 29450569
17
Relapse of rare diseases during COVID-19 pandemic: bicytopenia in an adult patient with thiamine-responsive megaloblastic anaemia.
Nouira N, Mansouri R, Tlili R, et al.
The Pan African medical journal 2020; (35(Suppl 2)):139 doi:10.11604/pamj.supp.2020.35.139.25368.
PMID: 33193954
18
Early thiamine therapy in Rogers syndrome: Systematic review of hematologic, auditory and glycemic outcomes.
Upadhyay Z, Sudani S, Jain A
Bioinformation 2026; (22(1)):26-30 doi:10.6026/973206300220026.
PMID: 41960466
19
Survey of patient satisfaction with genetic counseling services in Korea.
Choi IH, Kim YK, Yang SY, et al.
Journal of genetic counseling 2025; (34(1)):e1922 doi:10.1002/jgc4.1922.
PMID: 38769825

This page explains a child’s TRMA diagnosis and lifelong thiamine treatment for informational purposes only; it does not constitute medical advice. Discuss your child’s care plan with the treating team.